Sanofi offers Rs 10,000 crores bond linked to access medicine

The company said the costs of financing would be linked to achieving concrete targets in terms of a cumulative number of patients being provided with essential medicines over the next five years.

Published On 2022-04-01 09:36 GMT   |   Update On 2022-04-01 09:36 GMT
Advertisement

New Delhi: French healthcare group Sanofi said it had priced a first sustainability-linked bond issue that will be indexed on access to medicines, and worth 1.5 billion euros ($1.7 billion).

The company said the costs of financing would be linked to achieving concrete targets in terms of a cumulative number of patients being provided with essential medicines over the next five years.

The notes are set to be issued in two tranches of 850 million euros and 650 million euros respectively.

Advertisement

Read Also - Sanofi, Regeneron get CHMP recommendation for Dupixent approval to treat severe asthma with type 2 inflammation in kids

"We continue to make progress in our environmental, social and governance activities that are an essential part of our strategy and embedded into our business," said Sanofi chief financial officer Jean-Baptiste de Chatillon.

Read Also - Sanofi, IGM Biosciences collaborate for oncology, immunology, inflammation targets

Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. The Sanofi team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. Sanofi provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally while putting sustainability and social responsibility at the center of our ambitions.

Read Also - Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates












Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News